Great announcement and the switch to targeting cancer pain where we know fetanyl derived products have dominated is a good move. Alot of them have been pulled from shelves which will leave a big gap in the market in the coming years which gives inhalerx a chance to fill the void......
IND submission is overdue and should be lodged any day now!!!
Ann: IRX211 - Targeted Pain Indication Nomination - BTcP, page-2
Add IRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.933M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 95708 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 184000 | 1 |
View Market Depth
| Last trade - 10.04am 11/07/2024 (20 minute delay) ? |
| IRX (ASX) Chart |
Day chart unavailable